Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief that rapid-acting psychedelics like 5-MeO-DMT have the potential to transform the treatment resistant depression treatment landscape, the analyst tells investors in a research note. The firm added that, with pivotal milestones in the sector coming over the next 6-12 months and an update on the clinical hold anticipated this year, it believes GH is well-positioned for long-term upside.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research initiated with a Buy at Guggenheim
- GH Research initiated with an Outperform at RBC Capital
- GH Research PLC Reports 2024 Financial Results and Clinical Progress
- GH Research’s Promising Growth Potential: Buy Rating Backed by Strong Clinical Data and Financial Position
- Optimistic Buy Rating for GH Research Driven by Promising Clinical Data and Strong Financial Outlook
Questions or Comments about the article? Write to editor@tipranks.com